S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ALDX Aldeyra Therapeutics Inc

5.9762

-0.0838 (-1.38%)

Last Updated: 09:52:52

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics Inc News

Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 28 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 28 February 2025 (4 days ago) • Edgar (US Regulatory)

Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Tuesday 4 February 2025 (4 weeks ago) • Business Wire

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
Monday 2 December 2024 (3 months ago) • Business Wire

Form 8-K - Current report
Monday 18 November 2024 (3 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
Monday 18 November 2024 (3 months ago) • Business Wire

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
Thursday 14 November 2024 (4 months ago) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (4 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
Thursday 31 October 2024 (4 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Monday 21 October 2024 (4 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 3 October 2024 (5 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Thursday 3 October 2024 (5 months ago) • Business Wire

More Aldeyra Therapeutics Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions